Proficio Capital Partners LLC Makes New $567,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN

Proficio Capital Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, HoldingsChannel reports. The firm purchased 909 shares of the biopharmaceutical company’s stock, valued at approximately $567,000.

A number of other hedge funds have also modified their holdings of REGN. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $5,682,636,000. Norges Bank acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $1,012,296,000. Price T Rowe Associates Inc. MD raised its position in Regeneron Pharmaceuticals by 142.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after buying an additional 1,144,887 shares during the last quarter. Nuveen LLC raised its position in Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after buying an additional 835,240 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $473,872,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 0.9%

REGN stock opened at $807.71 on Friday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $847.00. The stock has a market cap of $83.16 billion, a price-to-earnings ratio of 19.96, a PEG ratio of 1.39 and a beta of 0.22. The business’s 50-day moving average is $713.83 and its 200 day moving average is $717.85.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period last year, the company posted $12.81 EPS. The business’s revenue was up 16.7% on a year-over-year basis. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the sale, the director directly owned 603 shares in the company, valued at $482,400. This represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,400 shares of company stock valued at $1,090,030. 6.97% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on REGN. Piper Sandler cut their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research note on Thursday, July 9th. Royal Bank Of Canada lifted their price objective on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. HSBC decreased their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a report on Monday, July 6th. Truist Financial upped their price objective on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. Fifteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $800.36.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone formation and progressive loss of movement. Approval gives Regeneron a new commercial product and strengthens its rare-disease portfolio. However, the small patient population may limit its immediate contribution to earnings. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: A Sound Shore Management investor letter highlighted Regeneron’s need to adjust its strategy following mixed results in melanoma drug trials. The commentary reflects ongoing investor debate about the company’s pipeline and long-term growth, while other market coverage indicates Wall Street remains reasonably constructive on the broader outlook. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Multiple law firms announced or promoted a securities class action concerning allegations that Regeneron misled investors about the prospects of the Phase 3 Fianlimab-Libtayo trial for advanced melanoma. The trial failure reportedly caused a major selloff and an approximately $11 billion decline in market capitalization. The allegations have not been proven, but the litigation adds reputational, legal, and disclosure risk; the lead-plaintiff deadline is September 14, 2026. Regeneron Investors Have Opportunity to Lead Class Action Lawsuit

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.